Top Markets
#1 NKN NKN +163.44%
#2 Bluwhale Bluwhale +34.86%
#3 Codatta Codatta +29.93%
#4 SAFEcoin SAFEcoin +28.49%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.47%
#7 Yooldo Games Yooldo Games +16.45%
#8 Particle Network Particle Network +16.23%
#9 TronBank TronBank +13.65%
#10 Arcblock Arcblock +13.56%
Coin of the day
NKN NKN
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rang in aandelen #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Aandeelprijs
$0.15
Marktkapitalisatie
$4.96M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
CA
Handel Intellipharmaceutics International Inc. (IPCIF)

Categorie

Healthcare
Dividendgeschiedenis van Intellipharmaceutics International Inc. (IPCIF)
Intellipharmaceutics International Inc. (aandelsymbool: IPCIF) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Intellipharmaceutics International Inc. (IPCIF) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
52.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
29.00%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL